| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
22,090,000 |
| Market
Cap: |
280.98(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$8.84 - $22.64 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile roGen Pharma is a biopharmaceutical company focused on developing and commercializing solutions that treat urothelial and specialty cancers. Co.'s approved product Jelmyto® (mitomycin) for pyelocalyceal solution, and its investigational candidate, UGN-102 (mitomycin) for intravesical solution, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer, respectively. In addition, Co.'s immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
17,153 |
34,717 |
38,517 |
46,176 |
| Total Sell Value |
$236,001 |
$512,810 |
$581,248 |
$648,111 |
| Total People Sold |
1 |
2 |
2 |
2 |
| Total Sell Transactions |
2 |
6 |
7 |
12 |
| End Date |
2024-03-15 |
2023-12-13 |
2023-06-14 |
2022-06-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Mullennix Stephen |
Chief Operating Officer |
• – – |
2019-02-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,034 |
7,034 |
|
- |
|
| Cohen Fred E |
Director |
– • – |
2019-02-06 |
4 |
OE |
$16.99 |
$254,850 |
D/D |
15,000 |
15,000 |
|
- |
|
| Schoenberg Mark |
Chief Medical OfficerOfficer |
• – – |
2019-01-01 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
12,986 |
|
- |
|
| Belldegrun Arie |
Director |
– • – |
2019-01-01 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
114,211 |
|
- |
|
| Schoenberg Mark |
Chief Medical OfficerOfficer |
• – – |
2019-01-01 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
5,287 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-11-28 |
4 |
S |
$40.51 |
$7,202,962 |
D/D |
(177,807) |
1,242,031 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-11-27 |
4 |
S |
$41.12 |
$1,294,910 |
D/D |
(31,491) |
1,419,838 |
|
- |
|
| Schreiber Alain |
10% Owner |
– – • |
2017-05-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,451,329 |
|
- |
|
158 Records found
|
|
Page 7 of 7 |
|
|
0.37 (2.83%) 
